Obesity and psoriasis: Body weight and body mass index influence the response to biological treatment

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 9, 2011, Pages 1007-1011

  Puig, L ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB;

BIOLOGICAL THERAPY; BODY MASS; BODY WEIGHT; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; HUMAN; MEDLINE; NONALCOHOLIC FATTY LIVER; OBESITY; OPEN STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE; WEIGHT CHANGE;

BIOLOGICAL AGENTS; BODY MASS INDEX; BODY WEIGHT; HUMANS; OBESITY; PSORIASIS; TREATMENT OUTCOME;

EID: 80051703774     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04065.x     Document Type: Review

References (41)

1. Bremmer S, Van Voorhees AS, Hsu S, et al. National Psoriasis Foundation. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am AcadDermatol 2010; 63: 1058-1069.
2. Lindegrd B,. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298-304. (Pubitemid 16014779)
3. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM,. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835. (Pubitemid 44556851)
4. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534. (Pubitemid 41815842)
5. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67. (Pubitemid 40981424)
6. Huerta C, Rivero E, Rodríguez LA,. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559-1565. (Pubitemid 350277774)
7. Setty AR, Curhan G, Choi HK,. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Int Med 2007; 167: 1670-1675. (Pubitemid 47280349)
8. Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingrd E, Sthle M,. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 492-497.
9. Jiang J, Torok N,. Nonalcoholic steatohepatitis and the metabolic syndrome. Metab Syndr Relat Disord 2008; 6: 1-7. (Pubitemid 351363913)
10. Gisondi P, Targher G, Zoppini G, Girolomoni G,. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
11. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-786.
12. Gerdes S, Rostami-Yazdi M, Mrowietz U,. Adipokines and psoriasis. Exp Dermatol 2011; 20: 81-87.
13. Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008; 217: 365-373.
14. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700-1721. (Pubitemid 36801943)
15. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J ClinPharmacol 2009; 49: 162-175.
16. Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am AcadDermatol 2010; 63: 571-579.
17. Nestorov I,. Clinical pharmacokinetics of TNF antagonists: How do they differ? Semin Arthritis Rheum 2004; 34 (Suppl. 1): 12-18.
18. Clark L, Lebwohl M,. The effect of weight on the efficacy of biologictherapy in patients with psoriasis. J Am Acad Dermatol 2008; 58: 443-446.
19. Strober B, Gottlieb A, Leonardi C, Papp K,. Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. J Am Acad Dermatol 2006; 54: AB220.
20. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006; 54 (Suppl.): S101-S111. (Pubitemid 43243481)
21. Menter A, Gordon K, Goldblum O, Gu Y,. Efficacy and safety of adalimumab are consistent across weight quartiles in patients with moderate to severe psoriasis: Subanalysis of REVEAL. J Am Acad Dermatol 2009; 60 (Suppl. 1): AB173.
22. Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM,. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010; 63: 448-456.
23. Kragballe K, Sygehus Å, Thaci D, Unnebrink K, Goldblum O,. Adalimumab plus topical treatment (calcipotriol/betamethasone) in the treatment of moderate to severe psoriasis: response across subgroups in BELIEVE. J Am Acad Dermatol 2010; 62 (Suppl. 1): AB133.
24. Saurat J-H, Unnebrink K, Goldblum O, Bissonnette R,. Adalimumab response is consistent across subgroups of patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. J Am Acad Dermatol 2010; 62 (Suppl. 1): AB124.
25. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4361b1-02-CENTOCOR. pdf (last accessed: 1 November 2010).
26. http://www.ema.europa.eu/humandocs/PDFs/EPAR/stelara/emeacombined-h958en. pdf (last accessed: 1 November 2010).
27. Griffiths CEM, Strober BE, Yeilding N, Menter A,. Ustekinumab treatment in patints with moderate-to-severe psoriasis who are nonresponders to etanercept: results from a phase 3 clinical trial. J Am Acad Dermatol 2010; 62 (Suppl. 1): AB137.
28. http://www.aad.org/Posters/Documents/AM2010/Poster/3357/3357.pdf (last accessed: 1 November 2010).
29. Reich K, Menter A, Plotnick M, Guzzo C, Li S, Gottlieb AB,. Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trials. Psoriasis Forum 2007; 13: 21-26.
30. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G,. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-1247.
31. Porres JM,. Jejunoileal bypass and psoriasis. Arch Dermatol 1977; 113: 983. (Pubitemid 8146848)
32. Higa-Sansone G, Szomstein S, Soto F, Brasecsco O, Cohen C, Rosenthal RJ,. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004; 14: 1132-1134. (Pubitemid 39299743)
33. de MenezesEttinger JE, Azaro E, de Souza CA, et al. Remission of psoriasis after open gastric bypass. Obes Surg 2006; 16: 94-97. (Pubitemid 43232247)
34. Hossler EW, Maroon MS, Mowad CM,. Gastric bypass surgery improves psoriasis. J Am Acad Dermatol 2010. Jul 21. [Epub ahead of print]
35. Nowlin N, Solomon H,. Weight loss and psoriasis [letter]. Arch Dermatol 1976; 112: 1465.
36. Pérez-Pérez L, Allegue F, Caeiro JL, Zulaica JM,. Severe psoriasis, morbid obesity and bariatric surgery. Clin Exp Dermatol 2009; 34: e421-e422.
37. Zackheim HS, Farber EM,. Rapid weight reduction and psoriasis. Arch Dermatol 1971; 103: 136-140.
38. Gisondi P, Cotena C, Tessari G, Girolomoni G,. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-344. (Pubitemid 351247425)
39. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57: 290-295.
40. Esposito M, Mazzotta A, Saraceno R, Schipani C, Chimenti S,. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J ImmunopatholPharmaco 2009; 22: 219-225.
41. http://www.ema.europa.eu/humandocs/PDFs/EPAR/humira/emeacombined-h481en. pdf (last accessed: 1 November 2010).